We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target several disease areas, ocular diseases and engineered cell medicines are two such zones where its pipeline is most mature.
- Recent EDIT Stock Price: $10.95
- Yearly Gain for EDIT stock: -68.85%
- Market Cap for EDIT stock: $757.08M
- P/E Ratio for EDIT stock: -3.753
Will EDIT's stock price go up? Is there an accurate EDIT stock forecast available?
TipRanks.com reports that Editas Medicine currently has 13 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $15.15. The target pricing ranges from a high EDIT forecast of $35.00 down to a low forecast of $7.00. Editas Medicine (EDIT)’s last closing stock price was $10.95 which would put the average price target at 35.62% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on EDIT stock.
Other analysts covering EDIT include:
- Joon Lee of Truist Financial issued a Buy rating with the price target of $ 35 on 23 hours ago
- Greg Harrison of Bank of America Securities issued a Hold rating with the price target of $ 15 on 23 hours ago
- Joel Beatty of Robert W. Baird issued a Buy rating with the price target of $ 18 on 23 hours ago
- Luca Issi of RBC Capital issued a Hold rating with the price target of $ 14 on 23 hours ago
If you are wondering if EDIT is a good stock to buy, here are 3rd party ratings for EDIT stock:
- TipRanks.com: Hold
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 19% (49 out of 252)
What is the sentiment on the street regarding Editas Medicine? (Current ratings compiled by TipRanks.com)
- News Sentiment for EDIT stock: Very Bullish
- Blogger Consensus for EDIT stock: Neutral
- Media Buzz for EDIT stock: Medium
- Insider Signal for EDIT stock: n/a
- Investor Sentiment for EDIT stock: Negative
- Hedge Fund signal for EDIT stock: Negative
The stock market is extremely volatile, and you need to do your own research on EDIT stock including scouring the social networks like EDIT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for EDIT stock chart >>
Summary: Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
- Recent IOVA Stock Price: $6.62
- Yearly Gain for IOVA stock: -62.73%
- Market Cap for IOVA stock: $1.12B
- P/E Ratio for IOVA stock: -2.864
Will IOVA's stock price go up? Is there an accurate IOVA stock forecast available?
TipRanks.com reports that Iovance Biotherapeutics currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $26.86. The target pricing ranges from a high IOVA forecast of $38.00 down to a low forecast of $16.00. Iovance Biotherapeutics (IOVA)’s last closing stock price was $6.62 which would put the average price target at 307.85% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on IOVA stock.
Other analysts covering IOVA include:
- Mark Breidenbach of Oppenheimer issued a Buy rating with the price target of $ 25 on 23 hours ago
- Mara Goldstein of Mizuho Securities issued a Buy rating with the price target of $ 30 on 23 hours ago
- Asthika Goonewardene of Truist Financial issued a Buy rating with the price target of $ 16 on 23 hours ago
- Joseph Pantginis of H.C. Wainwright issued a Buy rating with the price target of $ 38 on 23 hours ago
If you are wondering if IOVA is a good stock to buy, here are 3rd party ratings for IOVA stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 19% (49 out of 252)
What is the sentiment on the street regarding Iovance Biotherapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for IOVA stock: Neutral
- Blogger Consensus for IOVA stock: Bullish
- Media Buzz for IOVA stock: High
- Insider Signal for IOVA stock: Positive
- Investor Sentiment for IOVA stock: Very Negative
- Hedge Fund signal for IOVA stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on IOVA stock including scouring the social networks like IOVA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IOVA stock chart >>
Summary: EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors.
- Recent EDAP Stock Price: $9.95
- Yearly Gain for EDAP stock: 79.51%
- Market Cap for EDAP stock: $373.74M
- P/E Ratio for EDAP stock: 90.463
Will EDAP's stock price go up? Is there an accurate EDAP stock forecast available?
TipRanks.com reports that EDAP TMS currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.25. The target pricing ranges from a high EDAP forecast of $14.00 down to a low forecast of $11.00. EDAP TMS (EDAP)’s last closing stock price was $9.95 which would put the average price target at 23.12% upside.
In addition, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on EDAP stock.
Other analysts covering EDAP include:
- Swayampakula Ramakanth of H.C. Wainwright issued a Buy rating with the price target of $ 12 on 23 hours ago
- Jason Bednar of Piper Sandler issued a Buy rating with the price target of $ 12 on 1 day ago
- Michael Sarcone of Jefferies issued a Buy rating with the price target of $ 11 on 2 weeks ago
If you are wondering if EDAP is a good stock to buy, here are 3rd party ratings for EDAP stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 35% (88 out of 252)
What is the sentiment on the street regarding EDAP TMS? (Current ratings compiled by TipRanks.com)
- News Sentiment for EDAP stock: Neutral
- Blogger Consensus for EDAP stock: Bullish
- Media Buzz for EDAP stock: Very Low
- Insider Signal for EDAP stock: n/a
- Investor Sentiment for EDAP stock: n/a
- Hedge Fund signal for EDAP stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on EDAP stock including scouring the social networks like EDAP StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for EDAP stock chart >>
Summary: ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio.
- Recent VRAY Stock Price: $4.62
- Yearly Gain for VRAY stock: -14.70%
- Market Cap for VRAY stock: $852.65M
- P/E Ratio for VRAY stock: -7.85
Will VRAY's stock price go up? Is there an accurate VRAY stock forecast available?
TipRanks.com reports that Viewray currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $6.80. The target pricing ranges from a high VRAY forecast of $8.00 down to a low forecast of $5.50. Viewray (VRAY)’s last closing stock price was $4.62 which would put the average price target at 47.19% upside.
In addition, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on VRAY stock.
Other analysts covering VRAY include:
- Marie Thibault of BTIG issued a Buy rating with the price target of $ 7 on 1 day ago
- Neil Chatterji of B.Riley Financial issued a Buy rating with the price target of $ 8 on 2 days ago
- Jason Bednar of Piper Sandler issued a Buy rating with the price target of $ 6.5 on 2 weeks ago
- Rick Wise of Stifel Nicolaus issued a Buy rating with the price target of $ 7 on 2 months ago
If you are wondering if VRAY is a good stock to buy, here are 3rd party ratings for VRAY stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 35% (88 out of 252)
What is the sentiment on the street regarding Viewray? (Current ratings compiled by TipRanks.com)
- News Sentiment for VRAY stock: Very Bullish
- Blogger Consensus for VRAY stock: Neutral
- Media Buzz for VRAY stock: Low
- Insider Signal for VRAY stock: n/a
- Investor Sentiment for VRAY stock: Negative
- Hedge Fund signal for VRAY stock: Neutral
The stock market is extremely volatile, and you need to do your own research on VRAY stock including scouring the social networks like VRAY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VRAY stock chart >>
Summary: Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.
- Recent APLS Stock Price: $50.45
- Yearly Gain for APLS stock: -0.02%
- Market Cap for APLS stock: $4.78B
- P/E Ratio for APLS stock: -6.932
Will APLS's stock price go up? Is there an accurate APLS stock forecast available?
TipRanks.com reports that Apellis Pharmaceuticals currently has 14 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $76.14. The target pricing ranges from a high APLS forecast of $123.00 down to a low forecast of $40.00. Apellis Pharmaceuticals (APLS)’s last closing stock price was $50.45 which would put the average price target at 50.92% upside.
In addition, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on APLS stock.
Other analysts covering APLS include:
- Joseph Stringer of Needham issued a Buy rating with the price target of $ 70 on 23 hours ago
- Steven Seedhouse of Raymond James issued a Buy rating with the price target of $ 123 on 23 hours ago
- Anupam Rama of J.P. Morgan issued a Buy rating with the price target of $ 79 on 3 days ago
- Chris Howerton of Jefferies issued a Hold rating with the price target of $ 40 on 1 week ago
If you are wondering if APLS is a good stock to buy, here are 3rd party ratings for APLS stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 19% (49 out of 252)
What is the sentiment on the street regarding Apellis Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for APLS stock: Very Bullish
- Blogger Consensus for APLS stock: n/a
- Media Buzz for APLS stock: Medium
- Insider Signal for APLS stock: Neutral
- Investor Sentiment for APLS stock: Negative
- Hedge Fund signal for APLS stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on APLS stock including scouring the social networks like APLS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for APLS stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
